Literature DB >> 20452638

Sickle cell disease and the eye: old and new concepts.

Mohammed Elagouz1, Sreedhar Jyothi, Bhaskar Gupta, Sobha Sivaprasad.   

Abstract

The pathophysiology of sickle cell disease is not limited to abnormal red blood cells. The clinical manifestations of sickle cell disease include complex pathways and processes such as endothelial activation, inflammation, bioavailability of nitric oxide, oxidative stress, and the adhesiveness of a variety of blood cells. Increasingly, distinct subphenotypes and genetic modifiers of sickle cell disease are being recognized. We apply recent advances in sickle cell disease to ocular biology to highlight translational research in this field and encourage additional studies on the ocular manifestations of sickle cell disease. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20452638     DOI: 10.1016/j.survophthal.2009.11.004

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  36 in total

1.  Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.

Authors:  Wanwisa Promsote; Folami Lamoke Powell; Satyam Veean; Menaka Thounaojam; Shanu Markand; Alan Saul; Diana Gutsaeva; Manuela Bartoli; Sylvia B Smith; Vadivel Ganapathy; Pamela M Martin
Journal:  Antioxid Redox Signal       Date:  2016-08-22       Impact factor: 8.401

Review 2.  Neuroimaging of ocular involvement in patients with sickle cell disease and review of the literature.

Authors:  José Fernando Vallejo Diaz; Rafael Glikstein; Marlise Peruzzo Dos Santos; Carlos Torres
Journal:  Neuroradiol J       Date:  2017-01-03

3.  Human bulbar conjunctival hemodynamics in hemoglobin SS and SC disease.

Authors:  Justin Wanek; Bruce Gaynes; Jennifer I Lim; Robert Molokie; Mahnaz Shahidi
Journal:  Am J Hematol       Date:  2013-06-12       Impact factor: 10.047

Review 4.  New Ways to Detect Pediatric Sickle Cell Retinopathy: A Comprehensive Review.

Authors:  Daniel A Pahl; Nancy S Green; Monica Bhatia; Royce W S Chen
Journal:  J Pediatr Hematol Oncol       Date:  2017-11       Impact factor: 1.289

5.  A comparison of 23-gauge and 20-gauge vitrectomy for proliferative sickle cell retinopathy - clinical outcomes and surgical management.

Authors:  Jason Ho; Anna Grabowska; Marta Ugarte; Mahiul Mk Muqit
Journal:  Eye (Lond)       Date:  2018-05-22       Impact factor: 3.775

6.  Morphine promotes neovascularizing retinopathy in sickle transgeneic mice.

Authors:  Kalpna Gupta; Chunsheng Chen; Gerard A Lutty; Robert P Hebbel
Journal:  Blood Adv       Date:  2019-04-09

7.  Multifocal electroretinogram findings in sickle cell maculopathy.

Authors:  Laurence Beral; Marc Romana; Nathalie Lemonne; Yoann Garnier; Marie Billaud; Malik Acomat; Coralie Zorobabel; Maryse Etienne-Julan; Thierry David; Philippe Connes
Journal:  Eye (Lond)       Date:  2019-07-09       Impact factor: 3.775

8.  Study of correlation of nitrite levels with malonaldehyde and the prognosis of patients with sickle cell disease on hydroxyurea, Ceará-Brazil.

Authors:  Romélia Pinheiro Gonçalves; Darcielle Bruna Dias Elias; Hemerson Iury Ferreira Magalhães; Jacqueline Holanda de Souza
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

9.  Visual Function in Asymptomatic Patients With Homozygous Sickle Cell Disease and Temporal Macular Atrophy.

Authors:  Gilles C Martin; Charlotte Dénier; Olivia Zambrowski; David Grévent; Lenaïc Bruère; Valentine Brousse; Mariane de Montalembert; Dominique Brémond-Gignac; Matthieu P Robert
Journal:  JAMA Ophthalmol       Date:  2017-10-01       Impact factor: 7.389

10.  Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cell hemoglobin-C disease but not in sickle cell anemia.

Authors:  Clément Lemaire; Yann Lamarre; Nathalie Lemonne; Xavier Waltz; Sadri Chahed; Florence Cabot; Ioana Botez; Benoit Tressieres; Marie-Laure Lalanne-Mistrih; Maryse Etienne-Julan; Philippe Connes
Journal:  Clin Hemorheol Microcirc       Date:  2013-01-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.